Clark PE. Re: Durvalumab in combination with BCG for BCG-naive, high risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial. Eur Urol 2026 Feb 25:S0302-2838(26)01995-0. doi: 10.1016/j.eururo.2026.
PMID: 41748387